IGC Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IGC Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 220% in 3 years; of every extra $100 of sales, $903 became extra profit. Higher than 97% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $797 tied up three years earlier. More money tied up than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-11.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 52% of Healthcare companies in United States.
Cash Locked Ratio
$44For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $797 tied up three years earlier.
More money tied up than 86% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$903Sales grew 220% in 3 years; of every extra $100 of sales, $903 became extra profit.
Higher than 97% of Healthcare companies in United States.
Asset Productivity Ratio
+220% / -67%In 3 years sales changed by +220% while total assets changed by -67%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-43.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Lower than 66% of Healthcare companies in United States.
Tangible Assets Ratio
79%Of every $100 the company owns, $79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Healthcare companies in United States.
Tangible Net Worth Ratio
71%Of every $100 of net worth, $71 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 57% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
IGC Pharma, Inc. made a loss over the last year. IGC Pharma, Inc. owes $0.33 for every $1 it owns. IGC Pharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2025.
P/E ratio
LossIGC Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.18The share price is 4.18 times IGC Pharma, Inc.'s book value per share, higher than 67% of Healthcare companies in United States.
Market cap
$26 MThe total market value of all of IGC Pharma, Inc.'s shares at today's price (share price × number of shares), smaller than 81% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$6 MWhat IGC Pharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.06Net worth divided by the number of shares. The share price of $0.25 is 4.2 times this, which is the P/B above.
Return on equity (ROE)
-83.3%IGC Pharma, Inc. lost 83.3% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
Owes vs Owns
0.33×IGC Pharma, Inc. owes $0.33 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Dividend yield
NoneIGC Pharma, Inc. does not currently pay a dividend.
Revenue growth
-6%Revenue fell 6% in the year to Mar 2025, and grew 47% a year on average over 3 years.
Profit growth
LossIGC Pharma, Inc. made a loss in each of the last two years.
Profit margin
-560.3%IGC Pharma, Inc. lost $560 for every $100 of revenue.
Cash vs debt
Net cashIGC Pharma, Inc. held $0 M more cash than debt (net cash) at Mar 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For IGC Pharma, Inc.: $26 M ÷ $6 M (31 Mar 2026) = 4.2.
What is IGC Pharma, Inc.'s return on equity?
IGC Pharma, Inc. lost 83.3% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
How much does IGC Pharma, Inc. owe compared with what it owns?
IGC Pharma, Inc. owes $0.33 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Does IGC Pharma, Inc. pay a dividend?
No. IGC Pharma, Inc. does not currently pay a dividend.
Is IGC Pharma, Inc.'s revenue growing?
Revenue fell 6% in the year to Mar 2025, and grew 47% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.